SOST and osteogenesis imperfecta: To examine whether Apc001PE could inhibit the antagonistic effect of sclerostin on bone formation of OI mice, six-week-old hSOSTki.Col1a2+/G610C mice (hSOSTki.OI) were subcutaneously administrated with Apc001PE (12 mg/kg, twice per week) for six weeks.